Palleon Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.palleonpharma.com
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Phase 1
Completed
- Conditions
- Ovarian CancerCancerBreast CancerHead and Neck CancerNon Small Cell Lung CancerGastric CancerEGJEsophagogastric Junction CancerUrothelial CancerMelanoma
- Interventions
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Palleon Pharmaceuticals, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT05259696
- Locations
- 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
© Copyright 2025. All Rights Reserved by MedPath